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Introduction: ES-62, a phosphorylcholine (PC)-containing immunomodulator secreted by the
parasitic worm Acanthocheilonema viteae, protects against nephritis in the MRL/Lpr mouse
model of systemic lupus erythematosus (SLE). However, ES-62 is not suitable for development
as a therapy and thus we have designed drug-like small molecule analogues (SMAs) based
around its active PC-moiety. To provide proof of concept that ES-62-based SMAs exhibit
therapeutic potential in SLE, we have investigated the capacity of two SMAs to
protect against nephritis when administered to MRL/Lpr mice after onset of kidney
damage. Methods: SMAs 11a and 12b were evaluated for their ability to suppress antinuclear
antibody (ANA) generation and consequent kidney pathology in MRL/Lpr mice when admin-
istered after the onset of proteinuria. Results: SMAs 11a and 12b suppressed development of
ANA and proteinuria. Protection reflected downregulation of MyD88 expression by kidney
cells and this was associated with reduced production of IL-6, a cytokine that exhibits promise
as a therapeutic target for this condition. Conclusions: SMAs 11a and 12b provide proof of
principle that synthetic compounds based on the safe immunomodulatory mechanisms of
parasitic worms can exhibit therapeutic potential as a novel class of drugs for SLE, a disease
for which current therapies remain inadequate. Lupus (2015) 0, 1–6.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic
autoimmune disease in which inﬂammation and
organ damage is driven by the deposition of anti-
nuclear antibody (ANA)-containing immune com-
plexes, with glomerulonephritis a major cause
of morbidity. Despite recent advances in B cell-
targeting therapies, there remains urgent need
for safer, non-immunosuppressive therapies.1
Increasing epidemiological evidence that infection
with parasitic helminths can protect against allergic
and autoimmune inﬂammatory disorders has led to
clinical trials that suggest that ‘worm therapy’
shows promise in the treatment of inﬂammatory
conditions.2 Moreover, characterization of the
actions of helminth-derived immunomodulators in
preventing development of inﬂammatory disorders
in experimental models has facilitated the identiﬁ-
cation of potential novel drug targets.3 Consistent
with these advances, we have recently shown that
prophylactic administration of ES-62, an immuno-
modulator secreted by the ﬁlarial nematode
Acanthocheilonema viteae, can suppress ANA pro-
duction and consequent kidney damage in the
MRL/Lpr model of SLE4 by partially downregulat-
ing myeloid diﬀerentiation factor 88 (MyD88) in B
cells and kidney cells to reset the regulatory:eﬀector
B cell balance and desensitize renal eﬀector
function.4
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However, the use of living pathogens as therapy
is not ideal and to date, deﬁned parasite-derived
immunomodulators such as ES-62 have not been
exploited as treatments due, for example, to their
inherent problems of immunogenicity. We there-
fore recently designed a library of small drug-like
compounds based around the active phosphoryl-
choline (PC)-moiety of ES-62, and presented
proof of concept that these small molecule ana-
logues (SMAs) provide novel prototypes for devel-
opment of anti-inﬂammatory drugs for rheumatoid
arthritis.5 We now report that two of these mol-
ecules, the sulfones 11a and 12b, protect against
disease development when administered therapeut-
ically after the onset of kidney damage, in the
MRL/Lpr mouse and also by downregulating
MyD88 levels, with consequent reduction of ANA
and desensitization of kidney eﬀector mechanisms.
Methods
Female MRL/Lpr mice (Harlan-Olac) were main-
tained and assessed for proteinuria (Siemens
Multistix analysis) in accordance with Home
Oﬃce Licences PIL60/12183, PIL60/12950,
PPL60/4492 and the ethics review board at the
University of Glasgow.4 Endotoxin-free ES-62
and SMAs 11a, 12b and 19o (Figure 1) were pre-
pared as described previously.5 Following develop-
ment of proteinuria (>1mg/ml), MRL/Lpr mice
were treated twice-weekly with 11a, 12b or 19o
(each at 1mg in 100 ml phosphate-buﬀered saline
(PBS)) or with PBS alone (100 ml), subcutaneously.
Kidneys were ﬁxed and cryopreserved before
being snap frozen in optimal cutting temperature
(OCT) embedding medium, sectioned (7mm), and
stained with haematoxylin and eosin (H&E) or
periodic acid-Schiﬀ (PAS) before being visualized
(10 and 40 magniﬁcation) using an Olympus
BX41 camera. ANA were detected in mouse
serum using human epithelial type 2 (HEp-2)
slides (Antibodies Incorporated, USA) using a
ﬂuorescein isothiocyanate (FITC)-conjugated anti-
mouse immunoglobulin (Ig)G antibody (Vector,
USA) and visualized using an Axiovert ﬂuorescent
microscope at an original magniﬁcation of 63.
ANA levels in individual mice were determined by
endpoint dilution analysis.4 Single kidney cell sus-
pensions and supernatants were harvested and
bone marrow-derived macrophages (bmM) diﬀer-
entiated in vitro before being analysed for cytokine
production by enzyme-linked immunosorbent
assay (ELISA) and MyD88 expression by ﬂow
cytometry and Western blotting (25 mg/sample;
quantitative analysis by Image J software) as
described previously.4,5 For ﬂow cytometry, cells
were ﬁxed, permeabilized and stained for intracel-
lular MyD88 using a rabbit anti-mouse-MyD88
antibody (Abcam) followed by an FITC-
conjugated goat-anti-rabbit-antibody (Vector
laboratories).4,5
Statistical analysis of proteinuria was by two-
way analysis of variance (ANOVA) (Bonferroni’s
post-test) whilst all other data were analysed by
one-tailed Student’s t-test.
Results
Therapeutic administration of 11a and 12b
suppresses proteinuria in the MRL/Lpr mouse
A screen of drug-like SMAs based on the immuno-
modulatory PC-moiety of ES-62 identiﬁed 11a
and 12b as mimicking the ability of the para-
site product5 to suppress the Toll-like receptor
(TLR)-mediated production of cytokines that pro-
mote the IL-17/IL-22 inﬂammatory axis which has
been implicated in the pathogenesis of autoimmune
diseases, including lupus.4,5 Thus, the therapeutic
potential of 11a and 12b, relative to PBS and 19o,
a structurally related inactive SMA,5 was assessed
by twice-weekly administration (1 mg/dose) follow-
ing onset of detectable proteinuria (>1mg/ml; week
16) in female MRL/Lpr mice. Examination of the
data generated revealed that treatment with 11a
or 12b, but not 19o, suppressed proteinuria
(Figure 2(a)). However, all of the 12b-treated
mice developed some proteinuria (3mg/ml; data
not shown) and neither SMA prevented glomerular
hypercellularity (Figure 2(b)). Nevertheless,
Figure 1 Structures of SMAs 11a, 12b and 19o.
SMAs: small molecule analogues.
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protection against proteinuria was associated with
reductions in cellular inﬁltration of the kidney and
ANA production (Figure 2(b)–(d)).
Mechanism of SMA action
As with protection aﬀorded by ES-62,4 both SMA
11a and 12b induced downregulation of MyD88
expression by kidney cells (Figure 3(a)).
Moreover, when we analysed the levels of MyD88
in bmM derived from MRL/Lpr mice, as a surro-
gate for the inﬂammatory M1-like macrophages
inﬁltrating the kidney during active lupus, it was
found that in vitro treatment with 11a and 12b
(1 and 5 mg/ml), but not 19o (results not shown),
reduced the steady-state (to a comparable extent as
ES-62; Figure 3(b)) and lipopolysaccharide
(LPS)-upregulated levels of MyD88 in bmM
(Figure 3(c)). Moreover, this 11a and 12b-mediated
downregulation of MyD88 was associated with
inhibition of LPS-mediated pro-inﬂammatory
interleukin (IL)-6 responses (Figure 3(d)). Finally,
analysis of the kidney supernatants4 of mice treated
with 11a and 12b revealed that the protection
aﬀorded by the SMAs was associated with reduced
levels of IL-6 (Figure 3(e)).
Figure 2 SMAs 11a and 12b, but not 19o, suppress proteinuria and ANA when administered therapeutically. (a) SMAs 11a, 12b,
19o, and PBS were administered following development of proteinuria (>1mg/ml; arrow). Data presented are mean proteinuria
scores SEM where n¼ 6 mice for all groups, except 19o where n¼ 2 and bars indicate range. (b) H&E and PAS staining of kidney
sections from mice (after 22 weeks) treated with PBS, 11a or 12b at the indicated magnification with digital zoom images of
glomeruli incorporating 100 mm scale bars. (c) Representative images of ANA staining of HEp-2 slides using the indicated serum
dilutions from PBS-, 11a- or 12b-treated mice with ANA levels in individual mice shown in (d). SMAs: small molecule analogues;
ANA: antinuclear antibodies; PBS: phosphate-buffered saline; HEp-2: human epithelial type 2; H&E: haematoxylin and eosin;
PAS: periodic acid-Schiff.
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Discussion
SMAs 11a and 12b suppress the development of
proteinuria in the MRL/Lpr mouse, even after the
onset of pathology, suggesting that SMAs such as
these may have therapeutic potential in SLE.
Indeed, the relevance of their therapeutic action is
highlighted by reports that MyD88 signalling is
essential for pathogenesis in the MRL/Lpr
Figure 3 SMAs 11a and 12b suppress MyD88 signalling and downstream effector IL-6 responses in the kidney. (a) Flow
cytometric analysis (MFI) of kidney MyD88 expression in individual mice (week 22). (b) MyD88 expression by bmM5 stimulated
with LPS (1 mg/ml), ES-62 (2 mg/ml), 11a or 12b (both at 1 and 5mg/ml) for 18 hours: exemplar Western blot and quantitation of
MyD88/b-actin expression normalized to the ‘None’ (medium) control. (c) Flow cytometric analysis of MyD88 expression by bmM
treated with 11a or 12b (5 mg/ml, two hours) prior to stimulation with LPS for 18 hours. IL-6 release by these cells (d), and in the
kidney supernatants of PBS-, 11a- or 12b-treated (1 mg/dose) MRL/Lpr mice (e). SMAs: small molecule analogues; MFI: mean
fluorescence intensity; LPS: lipopolysaccharide; IL-6: interleukin-6; PBS: phosphate-buffered saline; bmM: bone marrow-derived
macrophages; MyD88: myeloid differentiation factor 88.
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mouse,6 in particular by promoting the generation
of interferon (IFN)a, IL-6 and ANAs required to
drive autoimmune renal disease.6,7 Dissection of
the pathogenic roles of MyD88 has indicated that
deﬁciency solely in B cells is suﬃcient to protect
against nephritis in both the MRL/Lpr and
Lyn–/– mouse models of lupus,8,9 as MyD88 signal-
ling is essential for ANA production, activation of
nephrotoxic T cells and glomerulonephritis.
Reﬂecting this, ES-62 suppresses production of
each of IL-6þ B cells, plasmablasts and ANA in
MRL/Lpr mice and its desensitization of hyper-
responsive B cells is associated with downregula-
tion of their MyD88 expression and accompanied
by an increased capacity of such B cells to express
FcgRIIb, which mediates negative feedback regula-
tion by immune complexes, and also produce the
regulatory cytokine, IL-10.4 Indeed, the ability of
splenic B cells from ES-62-treated MRL/Lpr mice
to suppress lupus nephritis in recipient animals
underlines the importance of downregulation of
MyD88 expression in the ES-62-mediated resetting
of the eﬀector:regulatory B cell balance.4
Consistent with these ﬁndings in experimental
models, MyD88 is required for the activation of
antibody-producing plasma cells in patients10 and
hence, together with its role in TLR/IL-1R signal-
ling, has been identiﬁed as a therapeutic target in
SLE.11 Moreover, given that ES-62 downregulates
expression of MyD88 during IL-1-mediated induc-
tion of T helper (Th)17 cells12 and that there is
evidence from studies on SLE patients that eﬀector
T cells are refractory to modulation by regulatory
T cells (Tregs),13 recent ﬁndings suggesting that
IL-1R-MyD88 signalling renders naive CD4þ
T cells refractory to Tregs to allow Th1/Th17 dif-
ferentiation14 provide an additional mechanism for
suppressing lupus pathogenesis by targeting
MyD88.
Like ES-62,4 SMA 11a and 12b act to maintain
renal ﬁlter barrier and kidney functionality, as indi-
cated by the signiﬁcantly lower levels of proteinuria
observed in treated mice, despite not inducing a
global improvement in kidney histopathology.
Rather, given its likely central role in integrating
pathogenic crosstalk amongst TLR, complement
and Fc receptors in SLE, this protection may be
explained by the downregulation of MyD88 render-
ing renal cells hyporesponsive to such proinﬂam-
matory stimuli. This hypothesis is supported by
the suppressed production of IL-6 by renal cells
from MRL/Lpr mice exposed to 11a or 12b, the
importance of which is reﬂected by the recent oﬀ-
label success of IL-6-targeting biologics (anti-IL-6R
monoclonal antibody (mAb), tocilizumab) in SLE
patients, as well as the current phase II trials with
anti-IL-6 mAbs in lupus nephritis (sirukumab) and
in a randomized clinical trial (RCT) in SLE
(PF-04236921).1 Moreover, whilst ES-62 selectively
suppresses inﬁltration of the kidney by inﬂamma-
tory T cells, neutrophils and M1-like macrophages,
it increases the levels of tissue-protective M2-like
macrophages that are deﬁcient in lupus.4
Intriguingly, therefore, given that ES-62 and
SMA 11a and 12b all downregulate MyD88 and
IL-6 expression by kidney cells in vivo, and their
inhibition of LPS-stimulated release of IL-6 by
bmM derived from MRL/Lpr mice is associated
with reduced MyD88 expression, it has recently
been reported that deletion of MyD88 in endo-
thelial and myeloid cells results in reduced recruit-
ment of M1-like inﬂammatory macrophages, and
abrogation of the pathogenic phenotypic switch
from protective M2- to pathogenic M1-like macro-
phages in adipose tissue, in an obesity-related
model of inﬂammatory disease.15
Perhaps surprisingly given their relative poten-
cies in suppressing proteinuria in MRL/Lpr mice,
SMA 12b was more eﬀective than 11a in suppress-
ing TLR4-mediated IL-6 production by bmM
in vitro. However, it should be noted that the
data obtained in vivo might be inﬂuenced by diﬀer-
ences in the pharmacokinetics of the two SMAs.
Nevertheless, our ﬁndings indicate SMA 11a to be
the more eﬀective at suppressing proteinuria.
By resetting the level of MyD88 signalling in both
inﬁltrating and resident kidney cells, SMAs such as
11a appear to act to suppress generation of patho-
genic ANA and consequent immune complex-
deposition and pro-inﬂammatory cell inﬁltration,
responses which in concert drive IL-6-mediated
lupus nephritis.7 Thus, such a drug-like compound,
based on the safe, natural immunomodulatory
action of ES-62 that has evolved over millennia to
suppress aberrant, but not protective, inﬂamma-
tion, may provide the starting point for the devel-
opment of novel therapies for SLE.
Funding
This work was supported by The Wellcome Trust
(086852/Z/08/Z). DTR held a Wellcome Trust
four-year PhD training studentship.
Conflict of interest statement
The authors have no conﬂicts of interest to declare.
Parasitic worm-based therapeutics for SLE
DT Rodgers et al.
5
Lupus
 at Glasgow University Library on July 21, 2015lup.sagepub.comDownloaded from 
Acknowledgements
DTR and MAP planned and performed experi-
ments and CJS designed and provided the SMAs.
WH and MMH planned and supervised the study.
All authors contributed to the analysis of the data
and preparation of the manuscript.
References
1 Stohl W. Future prospects in biologic therapy for systemic lupus
erythematosus. Nat Rev Rheumatol 2013; 9: 705–720.
2 Weinstock JV. Autoimmunity: The worm returns. Nature 2012; 491:
183–185.
3 Harnett W, Harnett MM. Helminth-derived immunomodulators:
Can understanding the worm produce the pill? Nat Rev Immunol
2010; 10: 278–284.
4 Rodgers DT, McGrath MA, Pineda MA, et al. The parasitic worm
product ES-62 targets myeloid differentiation factor 88-dependent
effector mechanisms to suppress antinuclear antibody production
and proteinuria in MRL/Lpr mice. Arthritis Rheumatol 2015; 67:
1023–1035.
5 Al-Riyami L, Pineda MA, Rzepecka J, et al. Designing anti-inflam-
matory drugs from parasitic worms: A synthetic small molecule
analogue of the Acanthocheilonema viteae product ES-62 prevents
development of collagen-induced arthritis. J Med Chemi 2013; 56:
9982–10002.
6 Sadanaga A, Nakashima H, Akahoshi M, et al. Protection against
autoimmune nephritis in MyD88-deficient MRL/Lpr mice. Arthritis
Rheum 2007; 56: 1618–1628.
7 Yung S, Cheung KF, Zhang Q, Chan TM. Mediators of inflam-
mation and their effect on resident renal cells: Implications in lupus
nephritis. Clin Dev Immunol 2013; 2013: 317682.
8 Teichmann LL, Schenten D, Medzhitov R, Kashgarian M,
Shlomchik MJ. Signals via the adaptor MyD88 in B cells
and DCs make distinct and synergistic contributions to
immune activation and tissue damage in lupus. Immunity 2013;
38: 528–540.
9 Hua Z, Gross AJ, Lamagna C, et al. Requirement for MyD88
signaling in B cells and dendritic cells for germinal center anti-
nuclear antibody production in Lyn-deficient mice. J Immunol
2014; 192: 875–885.
10 Capolunghi F, Rosado MM, Cascioli S, et al. Pharmacological
inhibition of TLR9 activation blocks autoantibody production in
human B cells from SLE patients. Rheumatology (Oxford) 2010;
49: 2281–2289.
11 Li J, Wang X, Zhang F, Yin H. Toll-like receptors as therapeutic
targets for autoimmune connective tissue diseases. Pharmacol Ther
2013; 138: 441–451.
12 Pineda MA, McGrath MA, Smith PC, et al. The parasitic helminth
product ES-62 suppresses pathogenesis in collagen-induced arth-
ritis by targeting the interleukin-17-producing cellular network at
multiple sites. Arthritis Rheum 2012; 64: 3168–3178.
13 Buckner JH. Mechanisms of impaired regulation by
CD4(þ)CD25(þ)Foxp3(þ) regulatory T cells in human auto-
immune diseases. Nat Rev Immunol 2010; 10: 849–859.
14 Schenten D, Nish SA, Yu S, et al. Signaling through the adaptor
molecule MyD88 in CD4þ T cells is required to overcome suppres-
sion by regulatory T cells. Immunity 2014; 40: 78–90.
15 YuM, Zhou H, Zhao J, et al. MyD88-dependent interplay between
myeloid and endothelial cells in the initiation and progression of
obesity-associated inflammatory diseases. J Exp Med 2014; 211:
887–907.
Parasitic worm-based therapeutics for SLE
DT Rodgers et al.
6
Lupus
 at Glasgow University Library on July 21, 2015lup.sagepub.comDownloaded from 
